22 November 2022: Original Paper
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma
Gonzalo Sapisochin 1ADE** , Wei Chen Lee 2ABCDE , Dong Jin Joo 3ABD , Jae-Won Joh 4ABE , Koichiro Hata 56BCDE , Arvinder Singh Soin 7ACDE , Uday Kiran Veldandi 8ABCDEF , Shuhei Kaneko 9ACDE , Matthias Meier 10ACDEG , Denise Leclair 11DE , Gangadhar Sunkara 11CDEF , Long Bin Jeng 12AB**DOI: 10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
Table 2 Number and percentage of patients in either immunosuppressive regimen by randomized treatment group and timepoint.
| ITI patients in H2307 | |||
|---|---|---|---|
| Months after transplantation | Regimen | EVR+rTAC N=56n/M (%) | sTAC N=61n/M (%) |
| Month 6 | EVR | 51/52 (98.1) | 0/60 |
| sTAC | 1/52 (1.9) | 60/60 (100.0) | |
| Month 9 | EVR | 51/52 (98.1) | 0/59 |
| sTAC | 1/52 (1.9) | 59/59 (100.0) | |
| Month 12 | EVR | 50/52 (96.2) | 3/58 (5.2) |
| sTAC | 2/52 (3.8) | 55/58 (94.8) | |
| Month 18 | EVR | 48/52 (92.3) | 3/57 (5.3) |
| sTAC | 2/52 (3.8) | 53/57 (93.0) | |
| Month 24 | EVR | 45/50 (90.0) | 3/55 (5.5) |
| sTAC | 2/50 (4.0) | 52/55 (94.5) | |
| Month 30 | EVR | 33/41 (80.5) | 3/44 (6.8) |
| sTAC | 4/41 (9.8) | 40/44 (90.9) | |
| Month 36 | EVR | 34/41 (82.9) | 4/44 (9.1) |
| sTAC | 4/41 (9.8) | 38/44 (86.4) | |
| Month 42 | EVR | 34/41 (82.9) | 4/44 (9.1) |
| sTAC | 4/41 (9.8) | 39/44 (88.6) | |
| Month 48 | EVR | 34/41 (82.9) | 5/42 (11.9) |
| sTAC | 4/41 (9.8) | 36/42 (85.7) | |
| Month 54 | EVR | 33/40 (82.5) | 6/42 (14.3) |
| sTAC | 6/40 (15.0) | 34/42 (81.0) | |
| Month 60 | EVR | 32/39 (82.1) | 5/41 (12.2) |
| sTAC | 6/39 (15.4) | 34/41 (82.9) | |
| Month 6 | EVR | 40/41 (97.6) | 0/45 |
| sTAC | 1/41 (2.4) | 45/45 (100.0) | |
| Month 9 | EVR | 40/41 (97.6) | 0/45 |
| sTAC | 1/41 (2.4) | 45/45 (100.0) | |
| Month 12 | EVR | 40/41 (97.6) | 2/45 (4.4) |
| sTAC | 1/41 (2.4) | 43/45 (95.6) | |
| Month 18 | EVR | 38/41 (92.7) | 1/45 (2.2) |
| sTAC | 1/41 (2.4) | 43/45 (95.6) | |
| Month 24 | EVR | 37/41 (90.2) | 3/45 (6.7) |
| sTAC | 2/41 (4.9) | 42/45 (93.3) | |
| Month 30 | EVR | 33/41 (80.5) | 3/44 (6.8) |
| sTAC | 4/41 (9.8) | 40/44 (90.9) | |
| Month 36 | EVR | 34/41 (82.9) | 4/44 (9.1) |
| sTAC | 4/41 (9.8) | 38/44 (86.4) | |
| Month 42 | EVR | 34/41 (82.9) | 4/44 (9.1) |
| sTAC | 4/41 (9.8) | 39/44 (88.6) | |
| Month 48 | EVR | 34/41 (82.9) | 5/42 (11.9) |
| sTAC | 4/41 (9.8) | 36/42 (85.7) | |
| Month 54 | EVR | 33/40 (82.5) | 6/42 (14.3) |
| sTAC | 6/40 (15.0) | 34/42 (81.0) | |
| Month 60 | EVR | 32/39 (82.1) | 5/41 (12.2) |
| sTAC | 6/39 (15.4) | 34/41 (82.9) | |
| EVR – everolimus; ITT – intent-to-treat; M – the total number of patients remaining in study; n – number of patients with event; N – the total number of patients in the treatment group; rTAC – reduced-dose tacrolimus; sTAC – standard-dose tacrolimus. | |||